妈富隆和米非司酮对围绝经期功能失调性子宫出血患者的临床疗效对比及对性激素的影响

The clinical efficacy of Marvelon and Mifepristone in the treatment of dysfunctional uterine bleeding in perimenopausal period and the effect on sex hormone concentrations

目的:观察妈富隆和米非司酮对围绝经期功能失调性子宫出血的临床疗效对比及对性激素的影响情况。方法:收集来无锡市妇幼保健院妇科门诊就诊的诊断为围绝经期功能失调性子宫出血的患者124例,将其随机分为观察组与对照组,每组62例。其中,观察组采用妈富隆治疗,对照组采用米非司酮治疗,然后对两组患者治疗前后的子宫内膜厚度、完全止血时间、临床疗效以及治疗前后的性激素水平进行比较。结果:治疗后两组患者的子宫内膜厚度均小于治疗前,且观察组患者的子宫内膜厚度小于对照组,完全止血时间短于对照组,而观察组患者的总有效率高于对照组,其差异具有统计学意义(P<0.05);治疗后观察组患者的E2、LH和FSH水平均低于对照组,且观察组患者治疗后的E2、LH和FSH水平均低于治疗前,其差异具有统计学意义(P<0.05)。结论:妈富隆对围绝经期功能失调性子宫出血患者的临床效果优于米非司酮,且降低患者性激素水平的能力高于米非司酮,推荐在临床上应用。

Objective： To compare the clinical efficacy of Marvelon and Mifepristone in the treatment of dysfunctional uterine bleeding in perimenopausal period and the effect on sex hormone concentrations. Methods：124 patients diagnosed with perimenopausal dysfunctional uterine bleeding were collected from our hospital and divided into the observation group and control group randomly,64 cases in each group. The observation group was treated with Marvelon,and the control group was treated with Mifepristone. The endometrial thickness and sex hormone levels before and after the treatment,complete hemostasis time,clinical efficacy between the two groups were compared. Results： After treatment,the endometrial thickness of the two groups was smaller than that before treatment,and the endometrial thickness in the observation group was smaller than that in the control group after treatment; complete hemostasis time was shorter than that in the control group; the total effective rate（ 98. 4%） in the observation group was higher than that in the control group（ 88. 7%）,all with significant difference（ P〈0. 05）.The levels of E2,LH and FSH in the observation group were lower than that in the control group after treatment,besides the levels of E2,LH and FSH in the observation group after treatment were lower than that before treatment,all with significant difference（ P〈0. 05）. Conclusions： The clinical efficacy of Marvelon on dysfunctional uterine bleeding in perimenopausal period is better than Mifepristone,which is more effective in reducing the level of sex hormone and worth recommending in clinical application.